Literature DB >> 24533992

[Neonatal outcome of fetal hyperechogenic bowel].

L Maillet1, R C Rudigoz2, R Buffin3, J Massardier4, P Gaucherand4, C Huissoud5.   

Abstract

OBJECTIVE: Echogenic bowel (EB) represents 1 % of pregnancy and is a risk factor of fetal pathology (infection, cystic fibrosis, aneuploidy). The aim of our study was to determine the fetuses' outcomes with isolated EB. PATIENTS AND METHODS: This is a retrospective study of all patients who presented singleton gestations with a fetal isolated echogenic bowel between 2004 and 2011 in two prenatal diagnosis centers. Search of aneuploidy, infection and cystic fibrosis was systematically proposed as well as an ultrasound monitoring.
RESULTS: On 109 fetus addressed for isolate echogenic bowel five had other signs associated and 74 had a real isolated echogenic bowel (without dilatation, calcification, intrauterine growth restriction). In 30 cases, the EB was not found. Eighty-five percent of the patients had in the first trimester a screening for trisomy 21. None fetus with isolated EB had trisomy, infection or cystic fibrosis. One fetus died in utero and one newborn died of a metabolic disease without digestive repercussions. DISCUSSION AND
CONCLUSION: The risk of trisomy 21 and the risk to have a serious disease appear low for the fetus with EB. It does not seem necessary to propose a systematic amniocentesis in case of isolated echogenic bowel.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Aneuploidy; Aneuploïdie; Cystic fibrosis; Fetal ultrasound; Hyperechogenic fetal bowel; Intestin hyperéchogène; Mucoviscidose; Échographie fœtale

Mesh:

Year:  2014        PMID: 24533992     DOI: 10.1016/j.gyobfe.2014.01.006

Source DB:  PubMed          Journal:  Gynecol Obstet Fertil        ISSN: 1297-9589


  1 in total

1.  Performance of Chromosomal Microarray Analysis for Detection of Copy Number Variations in Fetal Echogenic Bowel.

Authors:  Xiangqun Fan; Hailong Huang; Xiyao Lin; Huili Xue; Meiying Cai; Na Lin; Liangpu Xu
Journal:  Risk Manag Healthc Policy       Date:  2021-04-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.